IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma

IK-175, alone and with nivolumab, demonstrated a favorable safety profile, evidence of target engagement, and preliminary clinical activity in immune-refractory urothelial carcinoma. These data support continued development of AHR inhibitors to overcome adaptive immune resistance in solid tumors.